Why Clovis Oncology Stock Was Blasting Off Tuesday

Shares of Clovis Oncology (CLVS 38.98%) headed for the moon on Tuesday after the company reported positive interim phase 1/2 clinical trial results for one of its therapies on June 14, with its shares up by more than 65% as of 11 a.m. ET today before pulling back slightly.